Article Text

Download PDFPDF

407 Tumor associated mitochondria antigens (TAMAs) as target for cancer vaccine: from the mechanisms to the clinical validation
  1. Francesca Costabile1,
  2. Stefano Pierini2,
  3. Renzo Perales-Linares1,
  4. Adham Bear1,
  5. Cameron Koch1,
  6. Linette Gerald1,
  7. Beatriz Carreno1,
  8. Michael Lotze3,
  9. Costantinos Koumenis1 and
  10. Andrea Facciabene1
  1. 1University of Pennsylvania, Philadelphia, PA, USA
  2. 2Carisma Therapeutics, Philadelphia, PA, USA
  3. 3University of Pittsburgh, Pittsburgh, PA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background One of the major hurdles in immunotherapy is the lack of effective immunological antigens to specifically target cancer. Therefore, identification of novel tumor associated antigens (TAAs) continues to be a critically important requirement to expand the efficacy of modern immunotherapy approaches. Altered energy metabolism, excessive ROS production, and physical vicinity of the mtDNA to the OXPHOS are all factors associated with somatic mtDNA mutations in cancer. mtDNA mutaion meet all the criteria for an ideal vaccine: 1. Immunogenic 2. Specific to Cancer 3. Functionally important.

Methods Our group generated a dendritic cell (DC) vaccine using lysates of mitochondria derived from RENCA cells, a spontaneously arising renal adenocarcinoma harbouring mtDNA mutations. We already published that protective immunity was observed when the vaccine was used prophylactically and therapeutically. Since we detected a higher expression of the PD1/PD-L1 pathway upon vaccination, we combined the TAMAs vaccine with an ICI treatment and we analyzed how the combination of the two treatments impact the tumor growth, the immune system, the tumor microenvironment and its vasculature.

Results The combination of the TAMAs vaccine with an ICI empowers the vaccine efficacy due to higher CD8+ infiltrate and higher expression of IFNγ. Since the ability of tumor cells to capture and transfer mitochondria from neighbouring cells including endothelial cells, we analyzed a possible impact of the TAMAs vaccine re-routing toward tumor vasculature (figure 1B-C). Interestingly, in RENCA tumor bearing mice treated with TAMAs vaccine we observed significant tumor vasculature restructure and ‘normalization’. We validate these results in vitro by mimicking the in vivo tumor to endothelial cells mitochondria transfer (figure 1A) and subsequently TAMAs specific T recognition of the endothelial cells bearing the TAMAs obtained by the mitochondria transfer. To validate similar mechanisms in humans, we first analyzed mtDNA New Generation Sequencing (NGS) data on different cancer patients’ cohorts (total of 191) finding at least 31% of patient harbouring immunogenic mt missense mutations. Second, human healthy donor PBMCs were primed with peptides derived from these mtDNA mutations: strikingly, 100% of them responded to at least two peptides (figure 2B). Third, using patient tumors tissues we validated the mt transfer from tumor to endothelium and in line with our results, we identified specific tumor mt mutations associated with decreased tumoral CD31 staining, suggesting a specific T cell reactivity against the tumor vessels (figure 2).

Conclusions In conclusion, we validate the immunogenicity of TAMAs in human and unveil a new immunological mechanism of vasculature pruning.

Ethics Approval The study obtained ethics approval (805981) from University Laboratory Animal Resources (ULAR), that is responsible for the procurement, care, and use of all University-owned animals used for teaching, research, and testing, as approved by the Institutional Animal Care and Use Committee (IACUC) and as mandated by federal law and regulations.

Abstract 407 Figure 1

RENCA mitochondria are transferred to endothelial cells (EC) and TAMAs T cells are rerouted toward tumor vessels. (A) Mt transfer is visualized by immunofluorescence (in vtiro): with co-culture between mtGFP-RENCA cells and endothelial cells isolated from BalbC mouse lungs in red (4:1 ratio). (B) ELISpot assay: TAMAs-specific T cells react to endotheliail cells isolated from AB12 tumor. (C) Apoptosis evaluation in vivo of tumor associated endothelium, by TUNEL assay (red) +CD31 staining (green): CD31 cells in RENCA tumors are mainly killed when mice are treated with the combination of ICI + TAMAs vaccine, compared to the vaccination treatment alone.

Abstract 407 Figure 2

Human tumor cells transfer immunogenic mutated mitochondria to hman endothelium cells. (A) Immunofluorescence with OverNight co-culture between A498/mito-dsRed and HUVEC cells 9Green): mt transfer happens by tubulin Nanotubes formation. (B) ELISpot and IFN-? production evaluation: CD8+ cells from HLA-A*02.:01 healthy donors (just ND602) in figure), previously pulsed two times with homologous DCs harboring the specific peptide, reacted against 9mers peptides derived from mutated tumor mitochondria (B2, B3, R6). (C) Correlation between CD31 expression in tumor and presence of mutations correlates with lower expression of CD31 vessels marker in tumors, suggesting a hypothetical immune response against COX1 mutated peptide exposed on endothelial cells.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.